Skip to content

AnaptysBio, Inc. ANAB Accounts Payable

Accounts Payable at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.23B+5.8%
Eli Lilly logo
Eli LillyLLY
$5.03B+46.1%
Pfizer logo
PfizerPFE
$4.51B-14.0%
Amgen logo
AmgenAMGN
$2.94B+22.0%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.03B+45.6%
Biogen logo
BiogenBIIB
$358.5M-8.4%

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.73B+180%
Enterprise value$1.48B+176%
P/S7.4×+1.9×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.

The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about AnaptysBio, Inc.'s accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AnaptysBio, Inc.'s accounts payable?
AnaptysBio, Inc. (ANAB) reported accounts payable of $7.52M in Q1 2026.
How has AnaptysBio, Inc.'s accounts payable changed year-over-year?
AnaptysBio, Inc.'s accounts payable increased by 22.8% year-over-year, from $6.12M to $7.52M.
What is the long-term trend for AnaptysBio, Inc.'s accounts payable?
Over 5 years (2020 to 2025), AnaptysBio, Inc.'s accounts payable has grown at a -1.7% compound annual growth rate (CAGR), from $4.22M to $3.87M.
What does accounts payable mean?
Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.